Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States

Venetoclax is a BCL2 inhibitor approved for 17p-deleted relapsed/refractory chronic lymphocytic leukemia with activity following kinase inhibitors. We conducted a multicenter retrospective cohort analysis of patients with chronic lymphocytic leukemia treated with venetoclax to describe outcomes, tox...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Haematologica
Asıl Yazarlar: Mato, Anthony R., Thompson, Meghan, Allan, John N., Brander, Danielle M., Pagel, John M., Ujjani, Chaitra S., Hill, Brian T., Lamanna, Nicole, Lansigan, Frederick, Jacobs, Ryan, Shadman, Mazyar, Skarbnik, Alan P., Pu, Jeffrey J., Barr, Paul M., Sehgal, Alison R., Cheson, Bruce D., Zent, Clive S., Tuncer, Hande H., Schuster, Stephen J., Pickens, Peter V., Shah, Nirav N., Goy, Andre, Winter, Allison M., Garcia, Christine, Kennard, Kaitlin, Isaac, Krista, Dorsey, Colleen, Gashonia, Lisa M., Singavi, Arun K., Roeker, Lindsey E., Zelenetz, Andrew, Williams, Annalynn, Howlett, Christina, Weissbrot, Hanna, Ali, Naveed, Khajavian, Sirin, Sitlinger, Andrea, Tranchito, Eve, Rhodes, Joanna, Felsenfeld, Joshua, Bailey, Neil, Patel, Bhavisha, Burns, Timothy F., Yacur, Melissa, Malhotra, Mansi, Svoboda, Jakub, Furman, Richard R., Nabhan, Chadi
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Ferrata Storti Foundation 2018
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6119152/
https://ncbi.nlm.nih.gov/pubmed/29880613
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2018.193615
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller